Bariatric syringes under the brands “Wegovy”, “Ozempic” and “Mounjaro” are sold at In der Achat Apotheke in Mitte, Germany.
Image Alliance | Image Alliance | Getty Images
all doses Novo NordiskPopular weight loss injection Wegovy and diabetes drug Ozempic are now available in the U.S., according to one company renew Wednesday’s U.S. Food and Drug Administration drug shortage database.
It’s a sign that Novo Nordisk’s efforts to increase weekly supplies of the drug are starting to pay off as U.S. demand continues to soar
A previous update said Wegovy’s lowest dose (25 mg) remains in short supply.
Multiple doses of Wegovy and Ozempic’s active ingredient, semaglutide, have been on the FDA’s shortage list since early 2022 as demand surges in the U.S.
Wednesday’s update raises the possibility that the FDA may remove the blockbuster shots from its shortage list entirely, which could prevent compounding pharmacies from producing customized and often cheaper versions of these brand-name drugs.
Novo Nordisk said in a statement that all doses of Wegovy and Ozempic are regularly shipped to wholesalers. The Danish drugmaker said the FDA update was the result of its significant investment in expanding manufacturing capabilities and “ongoing communication” with the agency.
Still, Novo Nordisk said that even if a drug is listed as available, patients may not be able to immediately get their prescription filled at a specific pharmacy.
“Our intentional approach to gradually increasing supply in the U.S. market is working,” Novo Nordisk said. “We will continue to prioritize continuity of patient care, closely monitor market dynamics and chart prescribing trends.”
A week ago, Novo Nordisk asked the FDA to prevent the Compounding Pharmacy from producing unapproved versions of Wegovy and Ozempic, arguing that the drugs were too complex for manufacturers to produce them safely.
Earlier this month, the FDA removed the active ingredient in tirzepatide Eli Lilly and CompanyDiet drug Zepbound and diabetes treatment Mounjaro are both on its shortage list. But a trade group representing some of the compound’s manufacturers sued the FDA, and the agency said it would reconsider its decision to remove tilsiparatide from the shortage list.
About The Author
